What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating lease liabilities?

Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating lease liabilities has grown at a 80.8% compound annual growth rate (CAGR), from $549K to $10.6M.

What does operating lease liabilities mean?

Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Tarsus Pharmaceuticals, Inc. TARS Operating Lease Liabilities

Operating Lease Liabilities at other companies

Ocular TherapeutixOCUL

$4.23M-13.1%

Kodiak Sciences IncKOD

$44.33M-21.8%

Warby ParkerWRBY

$205.75M+0.5%

GlaukosGKOS

$35.31M-2.8%

Pulse Biosciences, Inc.PLSE

$5.53M-22.9%

Other financials

Income statement

See full

Revenue$162.1M+107%

Gross profit$152.7M+109%

Operating income-$6.1M+76.7%

Net income-$7.0M+72.3%

EPS (diluted)-$0.16+75.0%

Balance sheet

See full

Cash & equivalents$104.2M-41.6%

Total debt$88.7M+22.5%

Total equity$349.0M+1.9%

Total assets$581.1M+16.1%

Cash flow

See full

Operating cash flow-$24.7M-19.4%

CapEx$5.8M+886%

Free cash flow-$30.5M-43.4%

Valuation

See full

Market cap$2.85B+41.1%

Enterprise value$2.83B+47.8%

P/S5.3×-3.3×

Profitability

See full

Gross margin42.7%—

Operating margin-9.5%-4.2pp

Net margin-9%-4.0pp

FCF margin-28%-12.6pp

Returns & leverage

See full

Return on equity-14%-5.2pp

Debt / equity0.3×0.0×

Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s operating lease liabilities?: Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease liabilities of $16.08M in Q1 2026.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating lease liabilities?: Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating lease liabilities has grown at a 80.8% compound annual growth rate (CAGR), from $549K to $10.6M.
What does operating lease liabilities mean?: Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.